- Home
- VRTS vs SLS Comparison
VRTS vs SLS Comparison
Compare VRTS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRTS | SLS |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 924.5M |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | VRTS | SLS |
|---|---|---|
| Price | $167.45 | $13.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $158.00 | $10.00 |
| AVG Volume (30 Days) | 112.2K | ★ 5.8M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.68% | N/A |
| EPS Growth | 18.24 | ★ 50.00 |
| EPS | ★ 7.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.66 | $110.98 |
| P/E Ratio | $21.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $121.61 | $1.39 |
| 52 Week High | $203.61 | $15.88 |
Technical Indicators
Market Signals| Indicator | VRTS | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.93 | 59.35 |
| Support Level | $161.58 | $12.00 |
| Resistance Level | $170.30 | $15.88 |
| Average True Range (ATR) | 3.97 | 0.96 |
| MACD | -0.52 | 0.22 |
| Stochastic Oscillator | 58.85 | 76.14 |
Price Performance
Historical ComparisonAbout VRTS Virtus Investment Partners Inc.
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.